Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: At a median follow-up of 84 months, a trend for a better relapse-free survival was observed in the high-dose arm: (hazard ratio (HR) 0.84, P = 0.076, two-sided). The 621 patients with HER2/neu-negative disease benefited from high-dose therapy, while patients with HER2/neu-positive disease did not (test for interaction, P = 0.006). There was a marked relapse-free survival benefit for patients with HER2/neu-negative disease (71.5% versus 59.1%, 5 years after randomisation; HR 0.68, P = 0.002) and also a survival benefit (78.2% versus 71.0% at 5 years; HR 0.72, P = 0.02). CONCLUSIONS: The findings from this subgroup analysis provide additional evidence that HER2/neu-positive breast cancer is relatively resistant to alkylating agents. For HER2/neu-negative tumours, however, high-dose chemotherapy should remain the subject of clinical studies.
|
Authors | S Rodenhuis, M Bontenbal, Q G C M van Hoesel, W M Smit, M A Nooij, E E Voest, E van der Wall, P Hupperets, H van Tinteren, J L Peterse, M J van de Vijver, E G E de Vries, Netherlands Working Party on Autologous Transplantation in Solid Tumours |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 17
Issue 4
Pg. 588-96
(Apr 2006)
ISSN: 0923-7534 [Print] England |
PMID | 16446318
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Alkylating
|
Topics |
- Antineoplastic Agents, Alkylating
(adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, genetics, pathology)
- Dose-Response Relationship, Drug
- Female
- Genes, erbB-2
- Humans
- Immunohistochemistry
- Neoplasms, Second Primary
(chemically induced)
- Prospective Studies
- Survival Analysis
|